WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) Monday reported new positive data from the Phase 3 CAHtalyst Adult study of Crenessity in adults with classic congenital adrenal hyperplasia (CAH).
Congenital adrenal hyperplasia (CAH) is a group of genetic disorders that affect the Congenital adrenal glands.
One-year data from CAHtalyst Adult study showed lasting reductions in the dose of glucocorticoid, a class of steroid hormones, and improvement in clinical outcomes in adults with classic CAH. the results build upon previously reported one-year data from CAHtalyst Pediatric study.
These results were presented at the Endocrine Society's Annual Meeting, ENDO 2025.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
